Study of plasma vitamin D3 concentration as a modulator of lipid profile, inflammation and neurodegeneration in diabetic retinopathy in type 2 diabetes mellitus
Open Access
- 29 September 2025
- journal article
- Published by Publishing House Zaslavsky in Archive of Ukrainian Ophthalmology
- Vol. 13 (3) , 172-178
Abstract
Background. Vitamin D3 as a multifunctional biological agent actively participates in the pathogenesis of diabetic retinopathy (DR) in type 2 diabetes mellitus (T2DM), which allows researchers to consider it a potential biomarker for assessing patient status. We aimed to examine plasma vitamin D3 concentrations in patients with DR associated with T2DM and to analyze their correlations with parameters of inflammation, lipid metabolism, and neurodegeneration to identify new biomarkers. Materials and methods. We enrolled 106 patients (106 eyes) diagnosed with DR on the background of T2DM and divided them into subgroups according to the ETDRS severity scale. The study design included 3 groups: patients with non-proliferative DR (level 47–53e), moderate proliferative DR (level 61–75), and advanced proliferative DR (level 81–85). The control group included 64 relatively healthy individuals matched by age and sex. Plasma concentrations of vitamin D3, interleukin (IL) 1β, IL-10, ferritin, homocysteine, and non-neuronal enolase (NNE) were measured using enzyme-linked immunosorbent assay, and lipid profiles were analyzed. Statistical analysis was performed using IBM SPSS Statistics 23 and MedStat programs. Results. Patients with DR and vitamin D3 deficiency on the background of T2DM showed clear signs of chronic systemic inflammation and a relationship with NNE concentration, indicating more pronounced low-grade microglial inflammation in the brain and retina, a key mechanism underlying neurodegeneration and associated vision loss. This cohort also had a significant correlation between ferritin and IL-10 levels, but not IL-1β, which supports a differentiated approach to monitoring chronic systemic inflammation. Patients with advanced proliferative DR demonstrated significantly lower vitamin D3 levels if they were not receiving statin therapy. Conclusions. Plasma vitamin D3 concentration in patients with DR associated with T2DM serves as a biomarker for assessing neurodegeneration, systemic inflammation, and clinical outcomes, providing a basis for individualized patient management and DR prognosis. Statin therapy helps achieve stable compensation of vitamin D3 deficiency.Keywords
This publication has 29 references indexed in Scilit:
- Association of dietary niacin intake with diabetic retinopathy: A cross-sectional studyMedicine, 2025
- Intraplaque neovascularization and progression of atherosclerosis: A review of SMI technical assessment and berberine-statin regulatory mechanismsMedicine, 2025
- The Value of Baseline Intact Parathyroid Hormone in Vitamin D Supplementation for Early Multiple SclerosisMedical Principles and Practice, 2025
- Effect of vitamin D adjuvant therapy on the proportion of regulatory T cells in peripheral blood and pregnancy outcome of patients with recurrent miscarriageJournal of Obstetrics and Gynaecology Research, 2024
- Clinical importance of cytokine (IL-6, IL-8, and IL-10) and vitamin D levels among patients with Type-1 diabetesScientific Reports, 2024
- Vitamin D alleviation of oxidative stress in human retinal pigment epithelial cellsInternational Ophthalmology, 2024
- Impact of vitamin D deficiency on iron status in children with type I diabetesScientific Reports, 2024
- Adequate vitamin D status is associated with the reduced odds of prevalent diabetic retinopathy in African Americans and CaucasiansCardiovascular Diabetology, 2016
- IL-10 and IL-1β Mediate Neuropathic-Pain Like Behavior in the Ventrolateral Orbital CortexNeurochemical Research, 2015
- New Visual Acuity Charts for Clinical ResearchAmerican Journal of Ophthalmology, 1982